Vaccine Partnering During The Forecast Period 2017 – 2020: Global Deal Trends, Players And Financials

Researchmoz added Most up-to-date research on “Vaccine Partnering During The Forecast Period 2017 – 2020: Global Deal Trends, Players And Financials” to its huge collection of research reports.

The Global Vaccine Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in vaccine and adjuvant partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for vaccines
This report contains a comprehensive listing of all vaccine partnering deals announced since January 2009, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.
The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=487855
One of the key highlights of the report is that over 800 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.
 
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in vaccine dealmaking
2.1. Introduction
2.2. Vaccine partnering over the years
2.3. Vaccine partnering by deal type
2.4. Vaccine partnering by industry sector
2.5. Vaccine partnering by stage of development
2.6. Vaccine partnering by disease type
2.7. Partnering by specific vaccine technology type

Chapter 3 – Average financial deal terms for vaccine partnering
3.1. Introduction
3.2. Disclosed financials terms for vaccine partnering
3.3 Vaccine partnering headline values
3.4 Vaccine upfront payments
3.5 Vaccine deals with milestone payments
3.6 Vaccine deals with royalty rates

Designed by CyFocus.com
Powered by CyFocus.net
%d bloggers like this: